Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma

Inclusion Criteria

• •Age: 18 years of age or older
• •Non-, former or current smokers with a documented smoking history of ≤ 10 pack years
• •Asthma diagnosis as defined by the National Institutes of Health
• •Best FEV1 of 50% to \<80% of the predicted normal value
• •For current and former smokers, a post-albuterol FEV1/FVC ratio of \>0.70 at Visit 1/1a (between 5:00AM and 12:00 noon)
• •≥ 12% and ≥200mL reversibility of FEV1
• •Must have been using FP/SAL 250/50mcg inhalation powder BID for at least 2 weeks just prior to Visit 1.
• •Must be able to replace their current short-acting beta2-agonists with albuterol inhalation aerosol
• •Must be able and willing to give written informed consent to take part in the study.
• •Must be able and willing to comply with all aspects of the study including completion of daily e-Diary.